Advertisement
Advertisement
U.S. markets open in 3 hours 7 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Rocket Pharmaceuticals, Inc. (RCKT)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
15.94-0.45 (-2.75%)
At close: 04:00PM EST
16.03 +0.09 (+0.59%)
After hours: 04:01PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Engulfing Line (Bullish)

Engulfing Line (Bullish)

Previous Close16.39
Open16.99
Bid0.00 x 800
Ask0.00 x 900
Day's Range15.80 - 17.43
52 Week Range14.95 - 67.48
Volume514,245
Avg. Volume520,936
Market Cap1.027B
Beta (5Y Monthly)1.47
PE Ratio (TTM)N/A
EPS (TTM)-3.04
Earnings DateFeb 23, 2022 - Feb 28, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est65.33
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for RCKT

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Rocket Pharmaceuticals, Inc.
    RGNX: Lowering target price to $28.00REGENXBIO INC has an Investment Rating of HOLD; a target price of $28.000000; an Industry Subrating of High; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of High.
    Rating
    Fair Value
    Economic Moat
    8 days agoArgus Research
View more
  • Business Wire

    Rocket Pharmaceuticals Highlights Anticipated 2022 Milestones Across Lentiviral and AAV Gene Therapy Clinical Programs

    CRANBURY, N.J., January 11, 2022--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, today shares expected milestones for 2022, which were discussed yesterday during the Company’s virtual presentation at the 40th Annual J.P. Morgan Healthcare Conference.

  • Business Wire

    Rocket Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference

    CRANBURY, N.J., January 04, 2022--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, today announces that Gaurav Shah, M.D., Chief Executive Officer, will deliver a company presentation virtually at the 40th Annual J.P. Morgan Healthcare Conference on Monday, Jan. 10 at 1:30 p.m. ET.

  • Insider Monkey

    10 Healthcare Stocks to Buy According to Lee Ainslie’s Maverick Capital

    In this piece, we will take a look at the ten healthcare stocks to buy according to Lee Ainslie’s Maverick Capital. If you want to jump ahead to the top five stocks in this list and skip the details about Mr. Ainslie and his investment firm then head on over to 5 Healthcare Stocks to […]

Advertisement
Advertisement